Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
- Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
May 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- JPMA Nudges Govt to Take Special Measures for Infectious Disease Biz
May 9, 2023
- JPWA Urges Govt to Take Steps against Drug Shortages Based on Overseas Examples
May 9, 2023
- Trade Group Demands Better Market Environment for Regenerative Medicine, Proposes New Pricing Model
April 28, 2023
- Health Care Science Institute Proposes Policies for Solving Distribution Issues, Reviewing Pricing System
April 26, 2023
- Just Protecting Prices of On-Patent Meds Would Lead to 1.3% Growth in Japan: PhRMA
April 24, 2023
- Asian Pharma Groups Adopt Position Paper to Push E-Labeling
April 20, 2023
- Pharma CEOs Call for Japan’s Leadership to Tackle Global Health Issues at G7 Summit
April 17, 2023
- Japan, US, EU Trade Groups Push Price Maintenance during Patent Period: Joint Statement
April 17, 2023
- European Pharma CEOs Prod Japan to Rethink Drug Pricing System: Forum
April 13, 2023
- Scrap Numerical Target for Generic Use: Gx/Biosimilar Association to Govt
April 11, 2023
- Generic Use Rate Hits Record 81.2% in October-December: JGA
April 7, 2023
- JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
March 30, 2023
- JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
March 29, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…